CHEK1 and prostate carcinoma: Our real‐time RT‐PCR analyses revealed that CUDC‐907 treatment significantly decreased the transcript levels for CHK1, Wee1, RRM1 and RRM2 in prostate cancer cells, indicating a potential transcriptional mechanism responsible for the down‐regulation of these proteins by the agent.